Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

EBIAT Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances

Ratios

MoonLake Immunotherapeutics (MLTX) Long-Term Debt Issuances (2025 - 2026)

MoonLake Immunotherapeutics' Long-Term Debt Issuances history spans 2 years, with the latest figure at $24.5 million for Q1 2026.

Quarterly Long-Term Debt Issuances fell 66.49% to $24.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $24.5 million through Mar 2026, down 66.49% year-over-year, with the annual reading at $73.0 million for FY2025, N/A changed from the prior year.
Long-Term Debt Issuances came in at $24.5 million for Q1 2026, down from $73.0 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $73.0 million in Q1 2025 to a low of $24.5 million in Q1 2026.